Subcutaneous immunoglobulin substitution in primary B-cell defects. Review of the literature and some experiences with 17 patients over a period of 6 years;Subkutane immunglobulinsubstitution bei primären B-zell-defekten: Literaturübersicht und eigene erfahrungen mit 17 Patienten über einen Zeitraum von 6 Jahren

Tagliche Praxis

Volumn 46, Issue 1, 2005, Pages 185-194

  Busse, J ^a   Hoffmann, F ^a,b   Schlieben, S ^a   Strotmann, G ^a   Notheis, G ^a   Jansson, A ^a   Wintergerst, U ^a   Schmid, K ^a   Belohradsky, B H ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Home infusion therapy; Patients' acceptance; Primary immunodeficiencies; SCIG; Subcutaneous immunoglobulin therapy; Subcutaneous injections

Indexed keywords

BERIGLOBIN; GAMMANORM; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; SUBCUVIA;

ADULT DISEASE; ANAPHYLAXIS; B LYMPHOCYTE; B LYMPHOCYTE DEFECT; CHILDHOOD DISEASE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG PACKAGING; HOME CARE; HUMAN; IMMUNE DEFICIENCY; IMMUNOPATHOLOGY; IMMUNOTHERAPY; INFUSION; PATIENT ATTITUDE; QUALITY OF LIFE; REVIEW; SUBSTITUTION THERAPY;

EID: 14944344019     PISSN: 0494464X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Bruton OC. Agammaglobulinemia. Pediatrics 1952; 9: 722-728.
2. Roord JJ, et al. Home treatment in patients with antibody deficiency by slow subcutaneous infusion of gammaglobulin. Lancet 1982; 1: 689-690.
3. Eibl MM, Wolf HM. Immunglobulintherapie. In: Wahn U, Seger R, Wahn V, Hrsg. Pädiatrische Allergologie und Immunologie. 3. Aufl. München-Jena: Springer; 1999. S. 401-409.
4. Zielen S. Einsatz von Immunglobulinen bei angeborenen und erworbenen Immundefekten. In: Wahn V, Hrsg. Einsatz von Immunglobulinen bei angeborenen und erworbenen Immundefekten. 2. Aufl. Bremen: Unimed; 2000. S. 67-71.
5. Belohradsky BH. Klinisch anwendbare Immunglobuline. Fortschritte der antimikrobiellen und antineoplastischen Chemotherapie. Bd. 4-1. München: Futuramed; 1985.
6. Gardulf A, Hammarström L. Subcutaneous administration of immunoglobulins - What are the advantages? Clin Immunother 1996; 6: 108-116.
7. Baxter Deutschland GmbH. Die subkutane Heimselbstbehandlung mit Immunglobulin (Firmenprospekt). März 2003.
8. Berger M, Cupps R, Fauci A. Immunglobulin replacement therapy by slow subcutaneous infusion. Ann Intern Med 1980; 93: 55-56.
9. Gardulf A, Hammarström L, Smith CIE. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusions. Lancet 1991; 338: 162-166.
10. Avertis Behring GmbH Verkauf Deutschland. Fachinformation Beriglobin. August 2001.
11. Chapel HM, et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000; 20: 94-100.
12. Gardulf A. Rapid subcutaneous immunglobulin replacement therapy in patients with primary antibody deficieny: aspects of effectiveness, safty, home therapy, quality of life and costs (dissertation); Stockholm: Karolinska Institutet; 1994.
13. Borte M, et al. Efficacy and safety of Beriglobin applied subcutaneously to patients with primary immune deficiency (PID) - interim analysis after more than 1300 infusions. 10th Meeting of the European Society for Immunodeficiencies. Weimar, 17.-20. October 2002.
14. Waniewski J, Gardulf A, Hammarström L. Bioavailability of γ-globulin after subcutaneous infusions in patients with common variable immunodeficiency. J Clin Immunol 1994; 14: 90-97.
15. Ugazio AG, et al. Subcutaneous infusion of gammaglobulins in management of agammaglobulinaemia. Lancet 1982; 1: 226.
16. Thomas MJ, Brennan VM, Chapel HH. Rapid subcutaneous immunoglobin infusions in children. Lancet 1993; 342: 1432-1433.
17. Abrahamsen TG, Sandersen H, Bustnes A. Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies. Pediatrics 1996; 98: 1127-1131.
18. Gaspar J, Gerritsen B, Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child 1998; 79: 48-51.
19. Gardulf A, et al. Subcutaneous immunglobulin replacement in patients with primary antibody deficiencies: safty and costs. Lancet 1995; 345: 365-369.
20. Gardulf A, et al. Health-related quality of life in adults and children with primary immunodeficiencies before and during SCIG therapy. 10th Meeting of the European Society for Immunodeficiencies. Weimar, 17.-20. October 2002.
21. Licher Medizintechnologie, Pflege-Standard: Beriglobin Starter/Behandlungsset für die Spritzenpumpe Infusa T1 für subkutane Infusionen von Beriglobin.
22. Busse J, et al. Erfahrungen mit der subkutanen Immunglobulinapplikation bei 17 Patienten mit primären B-Zell-Defekten. 100. Jahrestagung der Deutschen Gesellschaft für Kinderheilkunde und Jugendmedizin. Poster KPH 26.3. Berlin, 9.-12. 9. 2004.